Project Overview
Study title: Managing Hypertension Among People Living with HIV: an InTegrated model (MAP-IT)
Study design: Stepped wedge cluster randomized control trial
Setting/location: Akwa Ibom State (30 primary health centers)
Study participants: HIV-positive patients over 18 years of age who are enrolled in HIV treatment services and have elevated blood pressure
Contact PI: Dike Ojji, University of Abuja (Nigeria)
MPIs: Angela Attah, Akwa Ibom State Primary Healthcare Development Agency (Nigeria); Juliet Iwelunmor, St. Louis University (USA); Gbenga Ogedegbe, New York University (USA)
Institutions supporting/advising: Washington University in St. Louis (USA), Akwa Ibom State Ministry of Health, Akwa Ibom State Primary Health Care Development Agency
Summary:
MAP-IT evaluates the effectiveness of practice facilitation on the integration of a task-shifting strategy for hypertension control (TASSH) into primary health centers. During the first phase (UG3), which took place in 2021-22, the study team employed the i-PARIHS framework to explore factors and support systems required for successful implementation and integration of TASSH into existing HIV chronic care platform, using that information to refine a context-specific practice facilitation strategy. During the implementation phase (UH3), MAP-IT will use the RE-AIM framework to study the effect of practice facilitation on TASSH adoption in primary health centers blood pressure control among 960 people living with HIV, and fidelity to TASSH and practice facilitation. Following the implementation stage, TASSH will continue at the PHCs without the support of practice facilitators. Six months following the start of the post-implementation stage, the study team will evaluate how well TASSH was sustained in the primary health centers.
· Meet Our Team ·
Dike Ojji, MD, PhD
University of Abuja, Abuja, Nigeria
Juliet Iwelunmor, PhD
Saint Louis University, St. Louis, Missouri, USA
Olugbenga G. Ogedegbe, MD
NYU, New York, New York, USA
Eno Angela Attah, MPH
MAP-IT is funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the US National Institutes of Health (NIH), through grant UH3-HL154498.